Page last updated: 2024-11-06

fluocinolone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Fluocinolone is a potent synthetic corticosteroid used topically to treat various skin conditions. It has anti-inflammatory, antipruritic, and vasoconstrictive properties. Fluocinolone's synthesis involves complex chemical reactions starting with a steroid precursor and proceeds through several steps. It exerts its effects by binding to glucocorticoid receptors in cells, modulating gene expression, and ultimately suppressing the inflammatory cascade. Fluocinolone is studied due to its effectiveness in treating a wide range of dermatological conditions, including eczema, psoriasis, and allergic dermatitis. Its potent anti-inflammatory properties make it a valuable therapeutic option, but it is essential to use it judiciously under medical supervision due to potential side effects, such as skin thinning and adrenal suppression.'
```

Cross-References

ID SourceID
PubMed CID91488
CHEMBL ID1201390
CHEBI ID5108
SCHEMBL ID2921319
MeSH IDM0108491

Synonyms (29)

Synonym
6-alpha-fluorotriamcinolone
6-alpha,9-difluoro-11-beta,16-alpha-17,21-tetrahydroxypregna-1,4-diene-3,20-dione
einecs 212-362-9
6-alpha,9-alpha-difluoro-11-beta,16-alpha,17-alpha,21-tetrahydroxypregna-1,4-diene-3,20-dione
pregna-1,4-diene-3,20-dione, 6-alpha,9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-
C07006
807-38-5
fluocinolone
chebi:5108 ,
CHEMBL1201390
(6s,8s,9r,10s,11s,13s,14s,16r,17s)-6,9-difluoro-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
ct1ix58l9s ,
fluocinolone [ban]
unii-ct1ix58l9s
6.alpha.-fluorotriamcinolone
fluocinolone [vandf]
16.alpha.-hydroxy-6.alpha.,9-difluoroprednisolone
pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-
fluocinolone acetonide impurity c [ep impurity]
pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,16,17,21-tetrahydroxy-, (6.alpha.,11.beta.,16.alpha.)-
SCHEMBL2921319
UUOUOERPONYGOS-CLCRDYEYSA-N
(6alpha,11beta,16alpha)-6,9-difluoro-11,16,17,21-tetrahydroxypregna-1,4-diene-3,20-dione
DB12553
Q27106662
DTXSID001016494
CS-0132766
6alpha-fluorotriamcinolone
HY-136642

Research Excerpts

Toxicity

The combination of ciprofloxacin plus fluocinolone is more effective than treatment with ciprafloxACin or fluoc in alone for AOMT. It is safe and well tolerated in children.

ExcerptReferenceRelevance
"7%) of the patients receiving fluocinolone presented with adverse events related to study medication."( Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
Ansley, J; Butehorn, HF; Byers, J; Douglis, F; Esterhuizen, K; Hernández, FJ; Hussain, I; Ismail, K; Lanier, B; Lansford, B; Pumarola, F; Spektor, Z, 2017
)
1.01
"The combination of ciprofloxacin plus fluocinolone is more effective than treatment with ciprofloxacin or fluocinolone alone for AOMT, and it is safe and well tolerated in children."( Efficacy and Safety of Ciprofloxacin Plus Fluocinolone in Otitis Media With Tympanostomy Tubes in Pediatric Patients: A Randomized Clinical Trial.
Ansley, J; Butehorn, HF; Byers, J; Douglis, F; Esterhuizen, K; Hernández, FJ; Hussain, I; Ismail, K; Lanier, B; Lansford, B; Pumarola, F; Spektor, Z, 2017
)
0.99

Compound-Compound Interactions

ExcerptReferenceRelevance
"We identified uveitic glaucoma patients with AGV surgery alone and AGV surgery combined with fluocinolone implant from the Massachusetts Eye and Ear Ocular Inflammation Database."( A retrospective study on the outcomes of Ahmed valve versus Ahmed valve combined with fluocinolone implant in uveitic glaucoma.
Cho, H; Davoudi, S; Guo, R; Lobo, AM; Papaliodis, GN; Sevgi, DD; Shen, LQ; Sobrin, L; Talcott, KE; Turalba, A, 2017
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
fluorinated steroidA steroid which is substituted with one or more fluorine atoms in any position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID90106Potency relative to fluocinolone 16,17-acetonide(Experimental vasoconstictor activity) in human; 15-451983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
AID188016Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate1983Journal of medicinal chemistry, Mar, Volume: 26, Issue:3
Structure-activity relationships in the antiinflammatory steroids: a pattern-recognition approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (21.52)18.7374
1990's12 (15.19)18.2507
2000's10 (12.66)29.6817
2010's27 (34.18)24.3611
2020's13 (16.46)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.37 (24.57)
Research Supply Index4.53 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index158.66 (26.88)
Search Engine Supply Index2.29 (0.95)

This Compound (80.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (13.58%)5.53%
Reviews10 (12.35%)6.00%
Case Studies12 (14.81%)4.05%
Observational2 (2.47%)0.25%
Other46 (56.79%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]